Evidence map›Paper›PMID 35794711›Full record

ArticleBriefings in bioinformatics2022

A comprehensive analysis of the IEDB MHC class-I automated benchmark.

Raphael Trevizani, Zhen Yan, Jason A Greenbaum, Alessandro Sette, Morten Nielsen, Bjoern Peters

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Raphael TrevizaniDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California 92037, USA.
Zhen YanBioinformatics Core, La Jolla Institute for Immunology, La Jolla, California 92037, USA.
Jason A GreenbaumBioinformatics Core, La Jolla Institute for Immunology, La Jolla, California 92037, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California 92037, USA.
Morten NielsenDepartment of Health Technology, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California 92037, USA.

Funding

IMMUNE EPITOPE AND ANALYSIS PROGRAM: Transplantation of organs, tissues and cells 75N93019C00001 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI WILSON, STEPHEN · 2019 to 2025
$23.1M
NIAID NIH HHS 75N93019C00001
6 · The paper itself

Abstract

In 2014, the Immune Epitope Database automated benchmark was created to compare the performance of the MHC class I binding predictors. However, this is not a straightforward process due to the different and non-standardized outputs of the methods. Additionally, some methods are more restrictive regarding the HLA alleles and epitope sizes for which they predict binding affinities, while others are more comprehensive. To address how these problems impacted the ranking of the predictors, we developed an approach to assess the reliability of different metrics. We found that using percentile-ranked results improved the stability of the ranks and allowed the predictors to be reliably ranked despite not being evaluated on the same data. We also found that given the rate new data are incorporated into the benchmark, a new method must wait for at least 4 years to be ranked against the pre-existing methods. The best-performing tools with statistically indistinguishable scores in this benchmark were NetMHCcons, NetMHCpan4.0, ANN3.4, NetMHCpan3.0 and NetMHCpan2.8. The results of this study will be used to improve the evaluation and display of benchmark performance. We highly encourage anyone working on MHC binding predictions to participate in this benchmark to get an unbiased evaluation of their predictors.

Indexed as

AllelesEpitopesProtein BindingReproducibility of ResultsEpitopesBenchmarkCD8+Epitope predictionIEDB toolsMHC-I

Identifiers

PMID35794711
PMCPMC9618166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.